Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to $21.9 million.

  • Protalix BioTherapeutics' Total Current Liabilities fell 939.31% to $21.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.9 million, marking a year-over-year decrease of 939.31%. This contributed to the annual value of $25.6 million for FY2024, which is 4372.72% down from last year.
  • Latest data reveals that Protalix BioTherapeutics reported Total Current Liabilities of $21.9 million as of Q3 2025, which was down 939.31% from $24.1 million recorded in Q2 2025.
  • Protalix BioTherapeutics' 5-year Total Current Liabilities high stood at $96.2 million for Q2 2021, and its period low was $21.9 million during Q3 2025.
  • In the last 5 years, Protalix BioTherapeutics' Total Current Liabilities had a median value of $33.2 million in 2021 and averaged $40.1 million.
  • In the last 5 years, Protalix BioTherapeutics' Total Current Liabilities plummeted by 6783.28% in 2022 and then soared by 15086.33% in 2024.
  • Over the past 5 years, Protalix BioTherapeutics' Total Current Liabilities (Quarter) stood at $33.2 million in 2021, then dropped by 2.25% to $32.4 million in 2022, then soared by 40.4% to $45.5 million in 2023, then crashed by 43.73% to $25.6 million in 2024, then dropped by 14.35% to $21.9 million in 2025.
  • Its Total Current Liabilities stands at $21.9 million for Q3 2025, versus $24.1 million for Q2 2025 and $24.3 million for Q1 2025.